Assessment of angiotensin converting enzyme gene polymorphism in patients with psoriasis

The Egyptian Journal of Immunology
Volume 29 (2), April, 2022
Pages: 19–25.
www.Ejimmunology.org
https://doi.org/10.55133/eji.290203
Nagwa I. Ashry1, Fadia M. Attia2, Amal H. Ahmed1, Hesham A. Nada1 and Ahmed I. Maaty3

 

1Dermatology, Venerology & Andrology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

2Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

3Physical Medicine, Rheumatology, & Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Corresponding author: Ahmed I. El-Sayed Maaty, Physical Medicine, Rheumatology & Rehabilitation Department, Faculty of Medicine, Suez Canal University, Ismailia, Ismailia Campus, Ring Road, Post-office No. 411522, Egypt.
Email: ahmed_maaty@med.suez.edu.eg

Abstract

Psoriatic patients had diversity of clinical presentations and complications. Psoriasis can have significant interference with the patient’s quality of life, recovery, and outcome. Some evidences suggest that the angiotensin converting enzyme (ACE) is present in the skin of psoriatic patients. This study intended to assess the patterns of ACE insertion/deletion (ACE ID) polymorphism and the levels of serum ACE among psoriatic patients in comparison to normal controls. The study included two groups: 20 patients with psoriasis and 20 apparently healthy adults with negative family history of psoriasis as a control group. Psoriasis area and severity index (PASI) was used to measure of severity of psoriasis. In both groups, ACE ID gene polymorphism was assessed by quantitative real-time polymerase reaction and serum ACE levels was evaluated using an enzyme-linked immunosorbent assay. ACE ID genotype was significantly higher among the psoriatic group in comparison to the control group (40.0% versus 15.0%, respectively, p=0.016). D allele was significantly higher among the psoriatic group than the control group (25.0% versus 7.5%, respectively, p=0.034). ACE ID genotype carried significantly higher risk in psoriatic group versus control group (OR=3.8). The D allele carried higher risk in psoriatic group versus control group (OR=4.1). ACE serum levels were significantly higher among the psoriatic group compared to the control group (87.4±7.03 versus 2.3±0.7, respectively; p<0.001). We concluded that ACE ID gene polymorphism may be considered as a risk factor for developing psoriasis.

Keywords: ACE polymorphism, psoriasis, ACE serum levels

Date received: 23 November 2021; accepted: 24 February 2022

PMID: 35436051

 

Full Text